Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent
about
Drug resistance analysis by next generation sequencing in LeishmaniaSingle dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c miceCurrent challenges in treatment options for visceral leishmaniasis in India: a public health perspectiveAdvances in Development of New Treatment for LeishmaniasisHealth economic evaluations of visceral leishmaniasis treatments: a systematic reviewMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisA poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appealLeishmania donovani develops resistance to drug combinationsFive-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, IndiaAntimony transport mechanisms in resistant leishmania parasites.Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.Vector saliva in vaccines for visceral leishmaniasis: a brief encounter of high consequence?Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.The household costs of visceral leishmaniasis care in south-eastern Nepal.Systematic literature review to evaluate and characterize the health economics and outcomes research studies in India.Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in BangladeshMolecular factors governing inhibition of arylimidamides against Leishmania: conservative computational modeling to improve chemotherapies.New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.Novel Agents against Miltefosine-Unresponsive Leishmania donovani.Short-Course Treatment Regimen of Indian Visceral Leishmaniasis with an Indian Liposomal Amphotericin B Preparation (Fungisome™).Liposomal amphotericin B as a treatment for human leishmaniasisSynthesis and structure-activity relationships of lansine analogues as antileishmanial agents.The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasisIntroducing single dose liposomal amphotericin B for the treatment of visceral leishmaniasis in rural bangladesh: feasibility and acceptance to patients and health staff.Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis.Leishmaniasis: new insights from an old and neglected disease.Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B.A Systematic Review of the State of Economic Evaluation for Health Care in India.A Mathematical Study to Control Visceral Leishmaniasis: An Application to South Sudan.Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).Nanostructured delivery systems with improved leishmanicidal activity: a critical review.Study of implementation and direct cost estimates for diagnostic tests for human visceral leishmaniasis in an urban area in Brazil.Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health.Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.Leishmaniasis in humans: drug or vaccine therapy?Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis.Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases
P2860
Q26851222-9C10582A-154F-4A63-95C5-BBCE2E715A1FQ27305906-6F074BAA-7AC7-4475-89DA-616363AB0E14Q28073426-150BFFDD-FB20-4D94-9FE2-8D88CC801167Q28082097-C11A4743-2B62-4D00-B0E7-C3639E422D53Q28084540-32742958-E583-467E-9006-D86307418433Q28271849-0FB3C84E-940B-45F4-BBCF-27E5688065B2Q28483975-FD672CD3-C65B-4B05-A7AC-EE68B5D01760Q28484463-05817A88-7EC2-46E4-B2DF-0F0B24E5A5FEQ28538265-8BBA0530-867D-4B1E-AAC8-CF1D5CAB908DQ33659312-4DD589D3-8037-4D8F-AD0F-DF3AA897BB01Q33783806-A67C66BB-77C8-4199-AC19-FC986EA97B9EQ34019064-12F41D19-1FFD-414F-BA1C-28254978A379Q34054948-823CA1A6-CAC0-4C2A-91B6-468A8136E4CEQ34328882-BF633A68-6DA9-4F2A-93E1-51A528F38A9AQ34613587-3C81E143-0C19-4FF4-A73B-1D583A93055EQ35041601-F369F822-B4E8-4690-9D54-8A9F27C7E8C5Q35065586-5A65E950-4413-41FA-A015-B4E0325BFF66Q35189818-E46336EC-00DE-4808-B45C-BC7E34878774Q35219247-28CFD47C-C9D4-46E7-8CD8-989A1291C088Q36290836-F9568517-7549-4E17-A527-4F37CCADCD3FQ36455848-F9E1B6A6-16BB-46E9-8464-F5E5B4B00EAFQ36456032-55D25CE2-A5D2-4D5B-A0AA-A36D2DBE6C11Q36589075-D13BBEB2-1878-47DA-B25A-94C7C5D14BEAQ36932080-A8A32C5E-793C-40FB-BA55-9332944F3A0BQ37569747-46A3D7CD-1877-4CE4-BB2C-4CE1E73F9701Q37811110-61C9EBCD-4FA9-48A4-BA67-FDAC5150CC8CQ37870821-0811C062-175C-4BFC-AAF9-7CE7594C12B8Q38376759-0C1C74C4-E33D-4B2B-B6E5-8B6E499B8C31Q38602629-55121F20-7CE4-484D-8AE7-C49F458904CAQ38867806-D9AAD3BA-D65D-458B-9F9D-64BD737E57FAQ39599468-4FD0DEBE-027E-474C-853B-AA404A8085D0Q40099567-C950D0D4-60D4-40F3-9A55-D4C0D4ADA08BQ40342021-AB5BEA6B-FE70-4119-9311-32E9B6479AE8Q43167558-EB17859D-A588-4F42-84BC-38874D117E40Q43561343-E42CC5BB-CD21-430C-9ED3-F8F9B1F82732Q45363637-FC69C2ED-3A04-4763-A6CD-B78F909F3C1CQ47556262-820A9AF4-ABCD-4FC3-9758-415B81135682Q50042596-7EFF66AA-D26B-47C9-B772-3A080474847AQ50677795-F0CDAC9F-E4E9-4E1A-8CE5-92E4799E1B63Q57347954-87CF1E47-1B7D-4F00-ADCC-10E0D62E7A75
P2860
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cost-effectiveness analysis of ...... sis in the Indian subcontinent
@ast
Cost-effectiveness analysis of ...... sis in the Indian subcontinent
@en
Cost-effectiveness analysis of ...... sis in the Indian subcontinent
@nl
type
label
Cost-effectiveness analysis of ...... sis in the Indian subcontinent
@ast
Cost-effectiveness analysis of ...... sis in the Indian subcontinent
@en
Cost-effectiveness analysis of ...... sis in the Indian subcontinent
@nl
prefLabel
Cost-effectiveness analysis of ...... sis in the Indian subcontinent
@ast
Cost-effectiveness analysis of ...... sis in the Indian subcontinent
@en
Cost-effectiveness analysis of ...... sis in the Indian subcontinent
@nl
P2093
P2860
P50
P921
P3181
P1476
Cost-effectiveness analysis of ...... sis in the Indian subcontinent
@en
P2093
Filip Meheus
Manica Balasegaram
Md Abul Faiz
Suman Rijal
P2860
P3181
P356
10.1371/JOURNAL.PNTD.0000818
P407
P5008
P577
2010-09-07T00:00:00Z